Winhealth Pharma Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Winhealth pharma group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Winhealth Pharma Group Today - Breaking & Trending Today

WinHealth and Immedica enter agreement giving Winhealth rights to [...] | Comunicati stampa CataniaOggi


31 dicembre 2020 08:22
Fonte: Adnkronos
#chimica-e-farmacia
STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.
Ravicti® is in Europe and North America indicated for treatment of urea cycle disorders (UCD), and under the announced partnership, WinHealth is granted a license to register and commercialize the product in UCD in the countries of the specified territory.
It is with great pleasure that we announce this partnership with WinHealth, under which we will be able to make Ravicti® available to UCD patients also in this part of the world. It also strengthens Immedica s geographical footprint, by introducing ....

United States , Republic Of , South Korea , Winhealth Pharma , Jack Wang , Anders Edvell , Prnewswire Hongkong Winhealth Pharma Group Co Ltd , Immedica Pharma , Greater China Area , North America , Cycle Disorder , Urea Cycle Disorders , Middle East , Winhealth Pharma Group , Ltd Oliver Hao , ஒன்றுபட்டது மாநிலங்களில் , குடியரசு ஆஃப் , தெற்கு கொரியா , பலா வாங் , அதிகமானது சீனா பரப்பளவு , வடக்கு அமெரிக்கா , மிதிவண்டி கோளாறு , யூரியா மிதிவண்டி கோளாறுகள் , நடுத்தர கிழக்கு , லிமிடெட் ஆலிவர் ஹ்ம் ,

WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries


Share this article
Share this article
STOCKHOLM and HANGZHOU, China, Dec. 30, 2020 /PRNewswire/ Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti
® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.
Ravicti
® is in Europe and North America indicated for treatment of urea cycle disorders (UCD), and under the announced partnership, WinHealth is granted a license to register and commercialize the product in UCD in the countries of the specified territory. ....

United States , Republic Of , South Korea , Oliver Hao , Winhealth Pharma , Jack Wang , Anders Edvell , Winhealth Pharma Group Co Ltd , Prnewswire Hongkong Winhealth Pharma Group Co Ltd , Winhealth Pharma Group , Immedica Pharma , Greater China Area , North America , Cycle Disorder , Urea Cycle Disorders , Middle East , Health Pharma , Pharma Group , Winhealth Pharma Group Hk , ஒன்றுபட்டது மாநிலங்களில் , குடியரசு ஆஃப் , தெற்கு கொரியா , ஆலிவர் ஹ்ம் , பலா வாங் , அதிகமானது சீனா பரப்பளவு , வடக்கு அமெரிக்கா ,